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Abstract
Background: Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is widely used for
quantitative proteomic investigations. The typical output of such studies is a list of identified and quantified
peptides. The biological and clinical interest is, however, usually focused on quantitative conclusions at the protein
level. Furthermore, many investigations ask complex biological questions by studying multiple interrelated
experimental conditions. Therefore, there is a need in the field for generic statistical models to quantify protein
levels even in complex study designs.
Results: We propose a general statistical modeling approach for protein quantification in arbitrary complex
experimental designs, such as time course studies, or those involving multiple experimental factors. The approach
summarizes the quantitative experimental information from all the features and all the conditions that pertain to a
protein. It enables both protein significance analysis between conditions, and protein quantification in individual
samples or conditions. We implement the approach in an open-source R-based software package MSstats
suitable for researchers with a limited statistics and programming background.
Conclusions: We demonstrate, using as examples two experimental investigations with complex designs, that a
simultaneous statistical modeling of all the relevant features and conditions yields a higher sensitivity of protein
significance analysis and a higher accuracy of protein quantification as compared to commonly employed
alternatives. The software is available at http://www.stat.purdue.edu/~ovitek/Software.html.
Background
Liquid chromatography coupled with tandem mass spec-
trometry (LC-MS/MS) is widely used for relative protein
quantification in complex biological mixtures. Several
quantification strategies have been described that can
broadly be grouped as those using stable isotope labeling
and label-free methods [1-3]. Label-free methods can be
further differentiated into methods based on spectral
counting [4] and methods that infer analyte quantities
from the ion current of the respective molecular ions.
The latter method has been implemented under the term
label-free LC-MS. It consists of the enzymatic digestion
of proteins into a mixture of peptides, the separation of
the peptides by capillary liquid chromatography, the ioni-
zation of the peptides, and the further separation of the
molecular ions by the mass spectrometer according to
their ratio of mass to charge. One instrument run yields
a two-dimensional LC-MS profile, where peaks corre-
spond to peptide ions, and the intensities of the peaks are
related to the abundances of the peptides. The molecular
ions representing specific LC-MS peaks can be further
fragmented in the mass spectrometer by collision acti-
vated dissociation to generate fragment ion spectra (MS/
MS), which are informative of the amino acid sequences
of the peptides. The label-free shotgun LC-MS/MS work-
flow [5,6] is popular because it requires minimal sample
processing and is relatively inexpensive. A variety of com-
putational tools are now available to detect, quantify, and
align LC-MS peaks across multiple samples and runs,
and to annotate them when possible with peptide and
protein identities [7].
The output of the LC-MS/MS workflow is a list of
features formed by identified, quantified, and aligned
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LC-MS peaks. Multiple features can represent a protein
when we observe differentially charged ions of the same
peptide, or several peptides of the protein. In many
investigations, specifically in systems biology [8] and in
the discovery of biomarkers of disease [9,10], it is neces-
sary and appropriate to summarize all the features into
protein-level conclusions. Such summarization has two
goals. First, protein significance analysis combines the
measurements for a protein across peptides, charge
states, and technical replicates across samples and con-
ditions, and detects proteins that change in abundance
between conditions more systematically than can be
expected by random chance. Second, protein quantifica-
tion combines the measurements for a protein within a
particular biological sample and estimates the abun-
dance of the protein in the sample, e.g., for use in clus-
tering or classification. Thus, the accuracy of both
protein significance analysis and protein quantification
has important implications for the biological or clinical
conclusions.
Many technologies other than LC-MS/MS require mea-
surement summarization, and the solution often involves
some form of averaging. E.g., in Affymetrix oligonucleotide
microarrays a gene is represented by 11-16 oligonucleo-
tides [11], and the expression of the respective gene is
quantified with Tukey median polish, implemented as part
of the robust multi-array averaging (RMA) normalization
and summarization [12,13]. Unfortunately, a similar such
summarization of the (log-)intensities of features mapped
to a protein fails to produce accurate results in label-free
LC-MS/MS, and it undermines the quality of the result
[14]. Unlike in microarrays where the probes are designed
and optimized, the LC-MS/MS workflow has little control
over the observed features. It yields proteins with features
that vary in number, have many interferences due to co-
eluting, mis-identified or mis-quantified peptides, and
have frequently missing intensities of peaks. Furthermore,
the peptide ions derived from a specific protein vary in
their ionization efficiency.
Measurement summarization in label-free LC-MS/MS
is improved by a probabilistic modeling, which explicitly
characterizes all the sources of variation. Such models
have been increasingly introduced into quantitative pro-
teomics and proven superior to averaging in both accu-
racy and sensitivity [14-19]. However, most of these
models are applicable to restricted experiment types,
e.g., the comparison of protein abundances between a
limited number of conditions. To compensate for the
variation and for the missing values, these models
require a fairly large number of biological replicates.
In this work, we argue that the accuracy of protein
significance analysis and protein quantification can be
enhanced by simultaneously studying a larger number of
experimental conditions, even when the number of repli-
cates in each condition is relatively small. Increasing the
number of conditions is advantageous biologically,
because a deeper insight can be obtained by considering
multiple inter-related conditions of the same model
organism, or by acquiring repeated measurements on
the same biological subject. It is also advantageous sta-
tistically, as it improves the accuracy of protein signifi-
cance analysis and protein quantification.
In previous work, we introduced the linear mixed effects
modeling framework for protein significance analysis and
protein quantification in label-free LC-MS/MS experi-
ments with simple, comparative designs [14]. The contri-
bution of the current manuscript is to extend this work to
arbitrary complex experimental designs, support the
proposed framework with a software solution, and demon-
strate the advantage of a joint modeling of multiple experi-
mental conditions to practitioners with a limited statistical
background. The open-source R [20]-based software pack-
age MSstats automatically recognizes the design of the
experiment, and can be used for both protein significance
analysis and protein quantification. We show that the fra-
mework provides meaningful results even with a moderate
number of biological replicates, and in experiments with
noisy and missing LC-MS peaks.
Methods
Dataset 1: A 3-way factorial study of breast cancer
cell lines
The study aimed at determining the effect of low oxygen
level (hypoxia) as compared to the normal oxygen level
(normoxia) on protein abundance in two breast cancer
cell lines, low-invasive MCF7 and high-invasive Hs578T.
Two cultures (biological replicates) of each cell line were
treated for either 6 or 24 hours in a normoxic or hypoxic
condition. The study had a complex design in that three
factors of interest, invasive potential (low, high), treatment
(hypoxia, normoxia), and time (6 h, 24 h), were examined
simultaneously (Figure 1). We refer to each of the eight
possible combinations of the factors as a condition. Since
separate cultures were grown in each condition, the
experiment had a 3-way factorial design.
Independent extraction procedures [21] were performed
on each culture (i.e., biological replicate), the order of the
samples was randomized, and three separate mass spectro-
metry runs (i.e., technical replicates) were acquired for
each sample on a hybrid LTQ-Orbitrap mass spectrometer
(ThermoFischer Scientific, San Jose, CA, USA), producing
48 runs. LC-MS features were quantified, aligned, and
annotated with peptide and protein identities using the
OpenMS software [22]. The feature intensities were log-
transformed and subjected to constant normalization [23].
The signal processing identified 278 proteins groups with
Clough et al. BMC Bioinformatics 2012, 13(Suppl 16):S6
http://www.biomedcentral.com/1471-2105/13/S16/S6
Page 2 of 17
two to 19 unambiguously mapped LC-MS features per
group, and with up to 40 missing peak intensities per
feature.
Additional details on the dataset are available in Sup-
plementary Section 1.
Dataset 2: A time course study of subjects with
osteosarcoma
The study was conducted at the Indiana University School
of Medicine in Indianapolis. It involved 14 subjects with
childhood osteosarcoma, for which serum samples were
collected at multiple time points during the course of
treatment, at the end of the treatment, and off-treatment
(Figure 2). During the course of the study, chemotherapy
and surgery were performed according to the Children’s
Oncology Group protocol P9754. In addition to the sub-
jects with osteosarcoma, the study involved 29 healthy
subjects for which blood samples were collected at a single
time point. The institutional review board at Indiana Uni-
versity approved the study protocol, and written informed
consent was obtained from all subjects before enrollment.
The study had a complex design in that it had two factors
of interest, disease (osteosarcoma, control) and time, and
multiple measurements on the disease subjects but not on
the controls. Therefore, the study had a combination of a
time course and a group comparison design. Due to the dif-
ficulty of obtaining samples from subjects in longitudinal
studies in a clinical setting, many subjects had missing
time points.
Albumin was depleted prior to tryptic digest, the order
of the samples was randomized, and each sample was
analyzed in single replicate runs using Thermo-Finnigan
linear ion-trap mass spectrometry, producing 130 runs.
LC-MS features were quantified, aligned, and annotated
with peptide and protein identities as previously described
[24]. When a peak was not detected in a run the workflow
reported the background noise, and therefore the dataset
had no missing peak intensities. The intensities were log-
transformed and subjected to quantile normalization [23].
To reduce the number of peptides with ambiguous map-
pings to protein isoforms, each peptide was mapped to the
underlying Entrez gene ID, and the signal processing iden-
tified 121 gene groups with two to 295 peptides per group.
For simplicity, we refer to the gene groups as proteins.
Proposed significance analysis
We define protein significance analysis as a sequence of
four steps: (1) statement of the problem, i.e., definition
of the comparisons of interest and of the scope of con-
clusions before collecting the data, (2) exploratory data
analysis, i.e., visualization of protein-specific features for
quality control, (3) model-based analysis, i.e., representa-
tion of the quantitative measurements in a probabilistic
model, and determination of proteins that change in
abundance between conditions, while controlling the
False Discovery Rate (FDR), and (4) statistical design of
the follow-up experiments. The four steps are common
to many experiments that study differences in analyte
abundance, and are described, e.g., in Chang et al. [25].
In this manuscript we emphasize the details that are
specific to label-free LC-MS/MS experiments with com-
plex designs.
Figure 1 Study of breast cancer cell lines. Two cultures from two breast cancer cell lines (low-invasive MCF7 and high-invasive Hs578T) were
treated with two oxygen levels (normoxia, hypoxia) for two periods of time (6 and 24 hours). We refer to each combination of these treatments
as condition. Separate cultures were grown in each condition, and therefore the experiment had a 3-way factorial experimental design.
Figure 2 Study of subjects with osteosarcoma. Chemotherapy treatment was administered according to the Children’s Oncology Group
protocol P9754. Blood samples were collected at the weeks indicated by colored boxes before chemotherapy was administered. The study had
a combination of a time course and a group comparison design.
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Step 1: Statement of the problem
Experiments with complex designs simultaneously
answer multiple related questions. In the study of breast
cancer cell lines we can compare, e.g., the abundance of
proteins between oxygen treatments in the high invasive
line, at a specific time point such as six hours of treat-
ment. Multiple other, similar questions could be asked
from the dataset. Although such comparisons can be per-
formed by separately analyzing the runs within the
respective conditions and ignoring the rest of the data,
we show in Section 3 that the joint modeling of all the
available conditions increases our ability to detect
changes that are relevant for the specific question asked.
As an illustration, here we compare the protein abun-
dance after six hours of normoxia in the low invasive ver-
sus the high invasive cell lines, on average over the
biological replicates. In the study of subjects with osteo-
sarcoma we compare protein abundance prior to surgery
(week 10) and post-surgery (week 13). The Step 3 below
enables arbitrary complex comparisons of this kind.
Statement of the problem also specifies the scope of the
conclusions, i.e., the interpretation that we attribute to the
biological and technical replication. The reduced scope of
biological replication means that we restrict our conclu-
sions to the subjects in the study, e.g., to the 43 subjects in
the study of osteosarcoma. This is appropriate for early-
stage screening experiments. The expanded scope of biolo-
gical replication means that we would like our conclusions
to hold beyond the selected subjects, and for the underly-
ing populations. E.g., in the study of subjects of osteosar-
coma this means that we expand our conclusions beyond
the selected 43 subjects, and to the entire population that
these subjects represent. This is necessary for experiments
at the validation stage. The choice of the scope is required
for all statistical models and all experimental designs
[25,26] and Step 3 below enables this choice. Section 3
illustrates that in addition to the important differences in
interpretation, the scope of biological replication impacts
the sensitivity and the specificity of the results. Therefore,
the scope of replication should be specified according to
the goals of the experiment, prior to collecting the data.
Step 2: Exploratory data analysis
Experiments with complex designs are more likely to
induce heterogeneous stochastic variation due to the
joint effects of multiple conditions on protein abun-
dance. Therefore, MSstats implements visualization
plots that assess the quality of the data and that can
help to guide the downstream analysis. A profile plot
such as in Figure 3(a) emphasizes quality control. The
plot helps a user to detect mis-identified features with
inconsistent quantitative profiles, or to remove features
with excessive quantitative interferences or missing
values. A trellis display [27] such as in Figure 3(b) visua-
lizes feature-level comparisons. It helps assess whether
the variation is homogenous across features and condi-
tions, and whether changes between conditions can
be due to the biological signal or to a technical artifact.
Figure 3(c) is an additional trellis display for time course
experiments, where each panel represents a subject. The
display allows us to evaluate the consistency of both
within-subject and between-subject changes in abundance.
The plots are generated automatically for all proteins
in MSstats with a one-line command. The proteins
selected in Figure 3 show only minor interferences in
feature intensities, and the large changes between condi-
tions appear systematic. An example of a protein with
interferences is given in Supplementary Section 1.2.
Step 3: Model-based analysis
The conclusions regarding changes in protein abun-
dance are formalized using statistical modeling and
inference. To represent a complex experimental design
we introduce a unique identifier for each condition, i.e.,
for each combination of the available experimental fac-
tors. For example, in the experiment of breast cancer
cell lines each combination of cell line type, oxygen
treatment, and exposure time forms one condition. In
the study of subjects with osteosarcoma, each combina-
tion of disease status and time forms one condition. We
further introduce a unique identifier for each subject,
i.e., for each biological replicate.
The proposed linear mixed effects model for the case of
factorial experiments is shown in Figure 4. The model
decomposes feature intensities of a protein into the con-
tributions of conditions (i.e., the differences in protein
abundance due to the factors of interest), LC-MS features
(i.e., the differences in average signal intensities between
the features), and biological replicates (i.e., the natural
biological differences in protein abundance between the
subjects). The model accounts for interferences in the
quantitative profiles of features across conditions with
the statistical interaction feature × condition. For time
course experiments the model is modified to account for
the between-subject heterogeneity of changes in protein
abundance in time (Figure 4). The model is designed for
a protein quantified by at least two features, but the
implementation in MSstats allows for proteins repre-
sented by a single feature by specifying a model without
the feature and feature × condition terms.
The model expresses the reduced scope of biological
replication by viewing the between-subject changes in
abundance as fixed values. Alternatively, it expresses the
expanded scope of biological replication by viewing these
changes as randomly sampled from the underlying popu-
lation. In practice a model with one of the two forms is
chosen based on the desired scope of conclusions, and is
specified for every protein quantified in the investigation.
We show in Section 3 that the reduced scope of replica-
tion leads to higher sensitivity of detecting changes in
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abundance as compared to the expanded scope of repli-
cation, but that this comes at the cost of a lower
specificity.
A property of label-free LC-MS/MS is that, in the
absence of technical replication, biological variation is
confounded with technical variation. Therefore, conclu-
sions from the model with reduced scope of biological
replication are also restricted to the performed mass
spectrometry runs, unless the experiment also incorpo-
rates technical replication.
The technical variation in the log-intensities of LC-MS
peaks is approximated relatively well by the Normal distri-
bution. However, the extent of this variation is not neces-
sarily constant across all features and conditions.
Specifying a separate variance parameter σ 2Error,ijk for each
feature, condition, and subject in experiments with com-
plex designs leads to a prohibitively large number of para-
meters and overfits the data. Instead, MSstats
implements the iterative least squares modeling procedure
[28]. Residual plots such as in Figure 5(a) visualize the
relationship between the predicted log-abundance and the
unexplained technical variation. The relationship is mod-
eled in a flexible loess fit [29] (Figure 5(b), Supplementary
Section 1.3), and LC-MS peaks with larger variances have
smaller weights in the resulting model-based conclusions.
A challenge in experiments with complex designs is in
deriving the comparisons in Step 1 from this compre-
hensive model. In the proposed approach this is
Figure 4 Linear mixed effects model for a factorial experiment. i = 1, ..., I is the index of a feature, j = 1, ..., J the index of a condition, k = 1, ..., K
the index of a biological replicate, and l = 1, ..., L of a technical replicate. Notation S(C)k(j) is read as “biological replicate within a condition”, and is
the unique identifier of each biological replicate. σ 2Error,ijk is the variance of the measurement error and σ
2
S the between-subject variance in the
underlying population. μ111 is the expected log-intensity of the arbitrary chosen first feature, first condition, and first biological replicate. (a) and (b)
are two alternative interpretations of the term subject, which distinguish reduced and expanded scopes of biological replication. A separate such
model is specified for each protein.
Figure 3 Exploratory data analysis in MSstats. Y-axis: Log-intensities, lines link log-intensities of LC-MS features, averaged over all replicates.
(a) Quality control: profile plot of the protein SLC44A2 in the study of breast cancer cell lines. X-axis: all conditions. (b) Feature-level
comparisons: trellis display of the protein SLC44A2 in the study of breast cancer cell lines. X-axis: one factor (time). Each panel: the combination
of the other factors. (c) Feature-level comparisons for time course experiments: trellis display of the Entrez ID 28299 of the study of subjects with
osteosarcoma. Each panel: a subject. X-axis: time.
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achieved by (1) translating each comparison into a
model-based quantity of interest, (2) expressing the
quantity as a linear combination of the model para-
meters, and (3) estimating this linear combination and
the associated standard error from the data, separately
for each protein. Figure 6 illustrates this for the factorial
study of breast cancer cell lines, and Figure 5 for the
study of subjects with osteosarcoma. In all investiga-
tions, a larger number of replicates provides a more
accurate estimation of the quantities.
The most difficult aspect of these steps is in determin-
ing the coefficients of the linear combination. The coef-
ficients depend on the comparison of interest, type,
number, and layout of the experimental factors, on the
numbers of features mapped to the protein, and on
whether we reduce or expand the scope of biological
replication. The implementation in MSstats automati-
cally derives all such expressions from the input dataset
and streamlines the testing for users with a limited sta-
tistics background. Finally, MSstats follows the stan-
dard testing procedure and calculates the ratio of the
estimated differences and theirs standard error (in statis-
tical terminology, the test statistic) for each protein, com-
pares the test statistics to the Student distribution with
the appropriate degrees of freedom to obtain p-values,
and adjusts the p-values for multiple comparisons to con-
trol the False Discovery Rate in the list of differentially
abundant proteins [30].
Step 4: Design of follow-up experiments
Sample size (i.e., the number of biological and technical
replicates per condition required to detect a fold change)
can be used to compare experimental strategies. In
experiments with complex designs it can indicate
whether the inclusion of additional conditions or time
points will help detect biologically significant changes
given the constraints of sample availability and cost. Sam-
ple size calculations based on linear models have been
described numerous times in general [31,32] and for pro-
tein significance analysis in particular [33,34]. They take
as input (1) q, the desired FDR in the protein list, (2) b,
the allowed probability of not detecting a change in
abundance on average over all the proteins (i.e., average
Type II error), (3) δ, the minimal fold change in protein
abundance that one would like to detect, (4) m0/m0 + m1,
the anticipated proportion of truly differentially abundant
proteins in the comparison, and (5) σ 2Error, the anticipated
technical variation (and also σ 2S , the anticipated biological
variation, for models with expanded scope of biological
replication). While (1)-(3) have generally accepted values,
(4)-(5) depend on the specific experiment and on its bio-
logical and technical variation. MSstats derives (4) and
(5) based on the current dataset, and calculates the sam-
ple size for a future investigation with a user-specified
number of features, conditions, and technical replicates
per condition, as described in reference [28] (see Supple-
mentary Section 1.3.6 for illustration). We use the special
Figure 5 Residual plots. Residual plots for protein CDH13 in the study of breast cancer cell lines. The protein has 16 features, residuals from the same
feature have the same color. (a) Residuals versus predicted peak log-abundance. (b) Absolute residuals versus predicted mean peak abundance are
modeled by a loess curve. Values on the curve predicted for each LC-MS peak are used as weights in the iterative least squares model fit.
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case of balanced datasets (i.e., datasets with the same
number of LC-MS runs in each condition and no missing
peaks) and a representative (e.g., median) variance over
all the proteins, for which the test statistic has a relatively
simple form (e.g., for the study of breast cancer cell lines
in Figure 6 and Supplementary Figure 3 with reduced
and expanded scope of biological replication, and Supple-
mentary Figures 5 and 6 for the time course study). Using
the comparison in Figure 6 as an example, a lower bound
on the fold change δ one can detect in a future investiga-






· (t1−β, df + t1−α/2, df )2,
where α = (1 − β) · q
1 + (1 − q) · m0/m1 ,
(1)
and t1-b, df and t1-a/2, df are the 100(1 - b)th and the
100(1 - a/2)th percentiles, respectively, of the t-distribu-
tion with df = IJK (L - 1) + (I - 1) J (K - 1) degrees of
freedom. From the formulae, given a fixed number of
features I, and a fixed number of biological replicates K
and technical replicates L per condition, increasing the
number of related conditions J increases the degrees of
freedom, which has the effect of decreasing the lower
bound of the detectable fold change. We show this
empirically in Section 3.
Proposed protein quantification
A distinct goal of label-free LC-MS/MS investigations is
protein quantification, i.e., the estimation of protein abun-
dance in a biological replicate, or in one condition on
average over all the replicates. In experiments with com-
plex designs these estimates are of a particular interest, as
they serve as input to machine learning tools to generate
new biological knowledge from the complex datasets. For
example, in the study of breast cancer cell lines we can
cluster the profiles of protein abundance across conditions
to find functionally related proteins. In the study of sub-
jects with osteosarcoma the profiles can be used to predict
the subject’s therapy response. Such estimates of abun-
dance differ from absolute protein quantification [35] in
that they are only comparable for a same protein across
conditions and runs, but not between proteins.
Here we argue that the accuracy of relative protein
quantification is enhanced by using the same probabilistic
Figure 6 Model-based comparison. Model-based comparison of protein abundance between cell line types after six hours of normoxia, with
reduced scope of biological replication. All notation is as in Figure 4. μ¯[high,nm ,6]. is the expected log-abundance of the protein in the high-
invasive line under normoxia, after 6 hours of exposure, on average in all the observed replicates. Other conditions are denoted similarly. “^”
indicates that the terms are estimated from the data.
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framework as in Section 2.3. Similarly to the testing, pro-
tein abundance in a sample or condition can be expressed
as a linear combination of the model parameters, and esti-
mated from the data together with its standard error.
Figure 7 illustrates the estimation of protein abundance
for the condition given by six hours of normoxia treat-
ment in the high invasive cell line in the factorial study of
breast cancer cell lines. Figure 7 illustrates a similar esti-
mation for the study of subjects with osteosarcoma. Figure
8 displays the quantifications and the associated confi-
dence intervals for one proteins in each study, which are
the same proteins as in Figure 3.
MSstats automatically derives the estimates and
streamlines the estimation. In Section 3, we show that
the accuracy and the precision of such protein quantifi-
cation is improved when simultaneously analyzing all
the available conditions.
Proposed treatment of missing LC-MS peaks
Experiments with complex designs are particularly sus-
ceptible to missing values, as they combine intertwined
effects of multiple conditions and a small sample size. An
advantage of linear mixed effects models is that they tol-
erate missing LC-MS peaks if each feature has at least
one intensity in each condition [14]. In the presence of
missing data the model-based estimates of abundance
differ from average log-intensities, and reflect more accu-
rately the available information. The estimates of varia-
tion are also adjusted. E.g., the confidence intervals in
Figure 8(a) vary in width due to the missing feature
intensities in the study of breast cancer cell lines, and in
Figure 8(b) due to missing time points in the study of
subjects with osteosarcoma.
When a feature is missing entirely in one condition,
this can be due to the low abundance, but also to other
reasons unrelated to abundance, e.g., post-translational
modifications, or even due to technical reasons. The
extent of missing values is influenced by the experimental
settings. There is currently no consensus on how to best
account for the missing data in this case. Some authors
advocate imputing missing intensities using the estimates
of background noise [24,36] or by using a classification
technique such as K-nearest neighbor [37]. Others argue
against imputation, and transform the peak intensities to
binary present/absent values [38], treat the missing inten-
sities as censored values as in survival analysis models
[18,39], or advocate testing a peptide for whether its
missing intensities occur more frequently in some experi-
mental groups than expected at random, in which case
the peptide is viewed as differentially abundant [40].
Since the goal of MSstats is to flexibly represent any
experimental situation, it does not enforce a one-size-
fits-all treatment of missing peaks. Instead it allows the
user to choose one of three options, based on prior bio-
logical expectations and on the exploratory data analysis
plots. First, the user can assume that the intensities
in the specific condition are missing due to low ion
abundance, and impute the missing values in this condi-
tion with the average minimum log-intensity across
runs. The analysis will reflect the interference in feature
intensities, but can violate the assumptions of Normality.
Second, the user can make no assumptions regarding the
reason for the missing values. This will require an alter-
native assumption that the features have no interference
(in other words, the model will not have the feature ×
condition statistical interaction in Figure 4). Model-based
estimates will account for the missing data, but signifi-
cance analysis may lose sensitivity. The third option is to
assume that this is a generally poor quality feature, and
remove it entirely from the dataset. In Section 3, we
show that the three treatments of the missing values have
only a small effect on the detection of differentially abun-
dant proteins.
Proposed open-source software implementation
MSstats is implemented in the open-source and open-
development environment R [20]. Although the models
for the factorial and the time course experiments are
Figure 7 Model-based quantification. Model-based quantification of the expected abundance of a protein in the high invasive cell line under
six hours of normoxia, on average over replicates of the condition. “^” indicates that the model-based quantities are estimated from the data.
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different, their specification in MSstats is identical.
The software requires a unique identifier for each biolo-
gical replicate, and uses the identities to detect the pre-
sence of repeated measurements and to internally
choose the correct model.
MSstats is a series of wrappers around the generic
methods lm in the library base and lmer in the library
lme4 [41]. lm fits linear models where all factors are
fixed, and estimates model parameters using ordinary
least squares [28,42]. MSstats uses this function for
models with reduced scope of biological replication.
lmer fits linear mixed effects models with an arbitrary
number of random effects, can handle large and unba-
lanced datasets, and estimates model parameters using
restricted maximum likelihood [43]. MSstats uses this
method for models with expanded scope of biological
replication.
The use of lm and lmer is adapted to the specifics of
LC-MS/MS. First, since each protein can have a differ-
ent number of features, a different number of model
terms (i.e., a different design matrix) is implemented for
each protein. Second, options are implemented to han-
dle heterogeneous variance and missing values. Finally,
MSstats automatically derives model-based summaries
for protein significance analysis and protein quantifica-
tion, such that the biological comparison is the only
input required from the user. Occasionally, it can be of
interest to perform an analysis at the feature level
instead of at the protein level, and MSstats also sup-
ports this option. Supplementary Information contains
R-based code for steps of the analysis. The software and
the documentation are publicly available at http://www.
stat.purdue.edu/~ovitek/Software.html.
Results
We illustrate the performance of the proposed framework
in the two case studies. As an example, for the study of
breast cancer cell lines, we compare protein abundances
between cell line types after six hours of normoxia (i.e.,
the comparison in Figure 6). In all the results, for features
with peak intensities missing in an entire condition the
values were imputed with the average minimum log-inten-
sity across all runs of the experiment (as implemented in
MSstats) unless stated otherwise. For the study of sub-
jects with osteosarcoma, we compare protein abundances
prior to surgery (week 10) and post-surgery (week 13), as
illustrated in Supplementary Section 2.2. The results for
both datasets were obtained with reduced scope of biologi-
cal replication unless stated otherwise.
Result 1: Joint modeling of all conditions improves the
sensitivity of protein significance analysis
Figure 9 illustrates the sensitivity of protein significance
analysis by using three approaches: (1) the proposed
Figure 8 Quantification of protein abundance in each condition. Quantification of protein abundance in each condition, on a relative scale
that is comparable between conditions of a protein but not between proteins. (a) Study of breast cancer cell lines, protein SLC44A2. (b) Study
of subjects with osteosarcoma, Entrez ID 28299. X-axis: condition. Y-axis: model-based estimate of protein log-intensity. Vertical lines are the 95%
confidence intervals. The selected proteins are the same as in Figure 3.
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analysis, i.e., the proposed joint modeling of all condi-
tions, (2) a pairwise analysis, i.e., a linear mixed effects
model that only represents the conditions in the compar-
ison, and (3) a naïve analysis, which averages feature
intensities in each replicate, retains the averages of repli-
cates corresponding to the conditions in the comparison,
and uses a t-test for protein significance analysis. The
pairwise analysis and the naïve analysis both only con-
sider measurements from conditions in the comparison
of interest. For the study of breast cancer cell lines, this
amounts to ignoring all the measurements on the cell
lines under the hypoxia treatment. For the study of sub-
jects with osteosarcoma, this amounts to retaining only
the measurements on subjects prior to surgery (week 10)
and post-surgery (week 13), and ignoring the rest.
The figure shows, for each analysis, the number of
proteins with an FDR-adjusted p-value below various
p-value cut-offs. The results indicate an increased sensi-
tivity of joint modeling over the pairwise analysis and the
naïve analysis in both case studies. While one can expect,
in general, a greater improvement in sensitivity by joint
modeling over the alternative analyses when fewer condi-
tions are considered in a comparison, the extent of the
sensitivity gain varies between experiments, and typically
increases with the sensitivity of the mass spectrometer,
and decreases with technical variation in the log-intensi-
ties and with the complexity of biological samples.
Result 2: Joint modeling of all conditions reduces the
required sample size
Figure 10 shows that a joint modeling of all conditions
requires a smaller number of biological replicates to detect
a given fold change than the alternative approaches, which
only use measurements from the particular conditions in
the comparison of interest. This is due to (1) the relation-
ship described in Step 4 of Section 2.3, i.e., increasing the
number of related conditions increases the available degrees
of freedom and reduces the lower bound of the detectable
standardized fold change, and (2) the fact that, although we
are only interested in a subset of the conditions, the entire
dataset is used to characterize the underlying variation, and
yields a more accurate estimate of the variation. The differ-
ence is particularly apparent for small fold changes.
In addition to the factors outlined in Section 2.3, the
sample size is strongly affected by the experimental
design. A time course design, such as in the study of sub-
jects with osteosarcoma, separates the within-subject and
the between-subject variation. Therefore, a comparison
of conditions (or time points) on the same subjects often
leads to a smaller required sample size. This is illustrated
by the smaller number of biological replicates in the time
course study of osteosarcoma in Figure 10(b) as com-
pared to the factorial design of breast cancer cell lines in
Figure 10(a). As before, the extent of such differences
depends on the specifics of the study.
Figure 9 Sensitivity of comparing protein abundance between conditions. Sensitivity of comparing protein abundance between conditions
as described at the beginning of Section 3. (a) Study of breast cancer cell lines. (b) Study of subjects with osteosarcoma. X-axis: p-values adjusted
to control for the FDR using the approach by Benjamini and Hochberg. Y-axis: number of significant proteins. Solid black line: the proposed joint
modeling of all conditions. Dashed red line: a linear mixed effects model that represents the conditions of interest, and ignores the rest of the data.
Dashed green line: a naïve analysis, which averages feature intensities in each replicate and uses a t-test for significance analysis.
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Result 3: Reduced scope of biological replication
increases the sensitivity at the expense of specificity
Figure 11 illustrates the sensitivity of the models in both
case studies. The figure shows that the reduced scope of
biological replication leads to a higher sensitivity of detect-
ing changes in abundance than the expanded scope. How-
ever, it has been previously demonstrated by simulation or
in experiments with known sample composition that the
sensitivity of the reduced scope of biological replication
comes at the expense of lower specificity of the compari-
sons [14,25,44].
Figure 12 illustrates the specificity of the models in the
study of breast cancer cell lines. For the purpose of illus-
tration, for each cell line we combined the exposure time
of the biological replicates under normoxia, and randomly
assigned them to two artificial groups. We compared pro-
tein abundances between these two artificial groups using
both reduced and expanded scope of biological replication,
and recorded the number of proteins with an FDR-
adjusted p-value below various p-value cut-offs. A model
that identifies fewer changes has higher specificity. Figure
12 illustrates the reduction in specificity in models with
reduced scope of biological replication as compared to
models with expanded scope of biological replication,
which successfully prohibit the discovery of any changes
in both cell lines. The trade-off of sensitivity and specificity
is a general and well-known property of reduced and
expanded scopes of conclusions; it extends to all model
types, and to all experimental designs.
Result 4: Joint modeling of all conditions improves the
precision and the accuracy of protein quantification
Figure 13 displays protein quantifications from the pro-
posed joint modeling of all conditions to those from the
naïve analysis, which are estimated by the averages of
log-intensities in each replicate. Error bars for each quan-
tification correspond to 95% confidence intervals, reflect-
ing the variability in the estimates. For the proposed joint
modeling, the variability is quantified as shown in Figure
7. For the naïve analysis, the variability is quantified by
the standard deviation of the averages. A majority of the
confidence intervals from the joint analysis are narrower
than those from the naïve analysis, indicating a higher
precision in the quantifications.
For the study of breast cancer cell lines, Figure 14
further investigates the accuracy of the two approaches
by comparing their standardized log-fold changes, i.e.,
test statistics, of the comparison of interest. The figure
illustrates that the joint modeling of the LC-MS/MS
intensities yields a fuller range of standardized log-fold
Figure 10 Sample size for comparing protein abundance between conditions. Sample size for comparing protein abundance between
conditions for a representative protein, in a future experiment with the same experimental structure. (a) Study of breast cancer cell lines. (b)
Study of subjects with osteosarcoma. X-axis: minimal fold change that we’d like to detect. Y-axis: the number of biological replicates per group.
Solid black line: the proposed joint modeling of all conditions. Dashed red line: a linear mixed effects model that represents the conditions of
interest, and ignores the rest of the data. Dashed green line: a naïve analysis, which averages feature intensities in each replicate and uses a
t-test for significance analysis. The anticipated proportion of differentially abundant proteins, the number of conditions and the number of
technical replicates are as in the current experiments. The number of features per protein and the error variance are set to the median values.
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Figure 12 Specificity of the proposed model with reduced versus expanded scope of biological replication. Specificity of the proposed
model with reduced versus expanded scope of biological replication in the study of breast cancer cell lines. Results from comparing protein
abundances between two artificial groups of replicates within (a) the low invasive cell line under normoxia and (b) the high invasive cell line
under normoxia. X-axis: p-values adjusted to control for the FDR using the approach by Benjamini and Hochberg. Y-axis: number of significant
proteins. Solid black line: reduced scope of biological replication. Dashed red line: expanded scope of biological replication.
Figure 11 Sensitivity of the proposed model with reduced versus expanded scope of biological replication. Sensitivity of the proposed
model with reduced versus expanded scope of biological replication for comparing protein abundances between conditions as described at the
beginning of Section 3. (a) Study of breast cancer cell lines. (b) Study of subjects with osteosarcoma. X-axis: p-values adjusted to control for the
FDR using the approach by Benjamini and Hochberg. Y-axis: number of significant proteins. Solid black line: reduced scope of biological
replication. Dashed red line: expanded scope of biological replication.
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changes, stemming from a more accurate representation
of the underlying variation in the log-intensities.
Result 5: Joint modeling of all conditions is relatively
robust to the choice of treatment of missing values
Due to different steps taken in data pre-processing, the
dataset of breast cancer cell lines, unlike the dataset of
subjects with osteosarcoma, contained numerous missing
peaks. Therefore, we used this study to investigate the
effect on the number of detected changes in abundance of
the three treatments of proteins where at least one feature
is missing entirely in at least one condition. We restricted
the list of proteins in the dataset to a subset of 140 pro-
teins with such missing values. Figure 15 shows the num-
ber of differentially abundant proteins obtained after (1)
imputation of the missing condition(s) with the estimate
of background intensity, (2) assuming no feature interfer-
ences, and (3) removing the feature from the dataset.
Panel (a) illustrates the results for the comparison used
throughout this section (low versus high invasive cell line
under normoxia, with 6 hours of exposure), and panel (b)
illustrates the same comparison, but on average over 6
and 24 hours of exposure times. The panels illustrate that
the majority of differentially abundant proteins were iden-
tified with all three approaches. Moreover, under nor-
moxia, the comparison in (b) has the same biological
interpretation as in (a), but it doubles the number of
biological replicates. As can be seen, the robustness of the
conclusions to the treatment of missing values increases
with the number of biological replicates.
Discussion
Our results show that in situations where measurements
are available from multiple related conditions, the pro-
posed joint probabilistic modeling and summarization of
all the LC-MS/MS runs leads to more sensitive protein
significance analysis and more accurate and precise pro-
tein quantification than when separately analyzing subsets
of conditions. The gain is due to a more efficient use of
the data, and to a more accurate understanding of the sys-
tematic and random variation.
A distinctive feature of linear mixed effects models is the
ability to distinguish two interpretations that we attribute
to biological replication. The expanded scope of biological
replication means that we expect to reproduce the results
in a new set of biological replicates that are randomly
selected from the underlying population. Significance test-
ing based on the expanded scope is conservative, and is
appropriate for confirmatory investigations. On the other
hand, a model specifying the reduced scope of conclusions
only expects to reproduce the results in a replicate mass
spectrometry analysis of the same biological samples.
Protein significance in these models may or may not be
reproduced in another set of biological replicates. Such
Figure 13 Precision of relative protein quantifications. (a) Study of breast cancer cell lines, protein SLC44A2. (b) Study of subjects with
osteosarcoma, Entrez ID 28299. X-axis: condition. Y-axis: model-based estimate of log-abundance. Vertical lines are the 95% confidence intervals.
Solid black lines: protein quantification based on the proposed joint modeling of all conditions. Dashed green lines: protein quantification based
on the naïve analysis, which averages feature intensities in each replicate. The proteins are the same as in Figure 3.
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models are appropriate for small-size screening experi-
ments. The distinction between the scopes of biological
replication is a property of all biological experiments, and
the advantage of linear mixed effects models is that they
make this distinction explicit, and allow practitioners to
make an informed choice. In all cases, the scope of conclu-
sions should be clearly specified prior to collecting the
data, the limits of generalizability should be clearly stated
when reporting the results, and the conclusions should be
followed by a thorough experimental validation.
Developing linear mixed effects models for experiments
with complex designs and making model-based conclu-
sions presents technical challenges for users with a limited
statistics background. The implementation in MSstats
automates these tasks and circumvents the challenges.
Table 1 summarizes the proposed analysis workflow,
Supplementary Table 2 annotates the steps of the work-
flow with R-based commands, and Supplementary Infor-
mation contains extensive code for implementing the
workflow in the two case studies. The analysis time of the
workflow increases with the dimensionality of the dataset
(i.e., with the number of quantified proteins, and the num-
ber of features per protein) and with the complexity of the
experiment (e.g., the model-based analysis for the time
course study of osteosarcoma requires a longer analysis
time than the factorial study of breast cancer), but even
for large-scale datasets from complex designs each step of
the workflow can typically be executed within minutes.
The proposed framework, and the software implemen-
tation, should not be confused with that of the recently
introduced software SRMstats for protein significance
analysis in label-based selected reaction monitoring
(SRM) workflows [25]. While also based on the linear
mixed effects modeling framework, the class of models
employed in SRMstats are designed to optimize perfor-
mance in datasets specific to the SRM workflow. SRM
datasets contain extra information from heavy-labeled
reference peptides, which facilitates several aspects of an
analysis, including normalization to remove systematic
between-run variation, separation of true biological
Figure 14 Accuracy of protein quantifications in the study of breast cancer cell lines. X-axis: standardized log-fold change, for the
comparison described at the beginning of Section 3, from the naïve analysis, which averages feature intensities in each replicate and uses a
two-group t-test. Y-axis: standardized log-fold change from the proposed joint modeling of all conditions. Dashed line: a 45° line.
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variation from non-systematic between-run variation,
and a more straightforward handling of missing values
within the linear mixed effects modeling framework. The
framework introduced in this work is designed
specifically for label-free LC-MS/MS investigations,
which are characterized by a confounding of variation
from multiple convoluted sources, heterogeneous sto-
chastic variation, frequent missing data, and greater
Table 1 An overview of the proposed data analysis workflow.
Steps Detailed tasks Comments
Statement of the
problem
• Specify comparisons of interest • Express comparisons as statistical hypotheses




• Detect mis-identified features • Remove obvious outliers
• Detect features with missing values • Choose imputation strategy
Model-based analysis • Fit linear mixed model per protein • Reduced scope of biological replication = fixed subjects; expanded
scope = random subjects
• Check qq-plots plots for Normality • If deviations, conclusions are approximate only
• Check residual plots for equal variance • If deviations, use iterative least squares
• Test comparisons of interest • Adjust p-values per comparison to control FDR
• Quantify protein abundance in conditions or
samples of interest
• Use as input with downstream clustering or classification
Design follow-up
experiments
• Evaluate power and sample size • Find minimal sample size for a fold change
• Find minimal fold change for a sample size
Supplementary Table 2 shows MSstats commands for each step.
Figure 15 Comparison of strategies for missing data. Effect of the treatment of missing LC-MS peaks on protein significance analysis in the
study of breast cancer cell lines, for the subset of 140 proteins where at least one feature is missing entirely in at least one condition. (a) Results
of comparing protein abundances between cell line types after six hours of normoxia. (b) Results of comparing protein abundances between cell
line types under normoxia, on average over the two exposure times. Each circle shows the number of differentially abundant proteins detected
with three treatments of features with peak intensities missing in an entire condition: (1) imputation of the background intensity, (2) assuming
no feature interferences, and (3) removing the feature from the dataset. The two comparisons have the same biological interpretation, but (b)
doubles the number of biological replicates.
Clough et al. BMC Bioinformatics 2012, 13(Suppl 16):S6
http://www.biomedcentral.com/1471-2105/13/S16/S6
Page 15 of 17
uncertainty in the conclusions. The implementation in
MSstats is designed to utilize experiments with com-
plex designs in order to better quantify the sources of
variation and reduce uncertainty.
The proposed approach has several limitations, most
of which are simplifications that reduce the complexity
and the analysis time of large-scale datasets. First,
MSstats requires the same treatment of missing peak
intensities to all proteins with excessive missings. A
user-specified protein-specific treatment, motivated by
the quality control plots, will likely be implemented in a
future version of the software. Second, MSstats applies
the same class of models to all proteins in the dataset.
While per-protein refinements, such as removing unne-
cessary interaction terms, are possible they are often
impractical, slow the analysis, require adjustments for
multiple testing, and may lead to more conservative
tests and overfitting. Another potential problem is the
assumption of Normally distributed random terms.
Although this assumption is rarely satisfied exactly, in
our experience the deviations from Normality on the
log-intensity scale are quite minor, and linear models
are known to be robust to such small deviations. Resi-
dual plots help diagnose features with major deviations,
which can then be manually excluded from the analysis.
The final limitation of the proposed approach is the
assumption that the LC-MS features in the dataset are
correctly identified, correctly mapped to protein groups,
and are informative of protein abundance (e.g., are
within the limits of the dynamic range). An incorrectly
mapped feature, a feature close to the edge of the signal
range, or a feature with a profile distorted by a post-
translational modification can undermine the quality of
the results. The quality control plots currently help par-
tially alleviate this issue.
Overall, the proposed approach balances accuracy and
practicality, and enables the analysis of complex experi-
ments in high throughput. Its open-source implementa-
tion is friendly to users with a limited statistics and
programming background. We hope that the proposed
approach will become a valuable tool for proteomic
investigations.
Additional material
Additional file 1: Supplementary information. Extensive experimental
and computational details and R code for MSstats are provided in
Supplementary information.
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